Quantitative Software System Sets Positron as the Leader in Diagnostic and Management Needs for Coronary Artery Disease.

HOUSTON -- Positron Corporation (OTCBB:POSC) announced today that the Company has finalized an agreement with the University of Texas at Houston and the Weatherhead PET Center headed by Dr. K. Lance Gould granting Positron a license to develop and commercialize an integrated comprehensive software system developed for the major diagnostic and management needs in coronary artery disease.

The software system includes the validated quantification of coronary blood flow images by PET Longitudinal Gradient Analysis and Homogeneity Algorithm (LGA/HA) to determine severity of coronary disease as the objective non-invasive basis for or against coronary bypass surgery or stent procedures and the automated objective analysis of CT or invasive coronary angiograms and a comprehensive database management system. The addition of the LGA/HA enables the Positron device to identify early coronary artery disease before clinically significant blockages develop. The quantitative accuracy provides non-invasive follow-up of treatment effectiveness in long-term studies documenting the prevention, stabilization or reversal of coronary artery disease in most patients. The Coronary Arteriographic Tree analysis program integrates 35 years of fluid dynamic research into automated quantification of the entire coronary artery tree for diffuse atherosclerosis as well as multiple blockages in all coronary arteries and branches on a CT or invasive coronary arteriogram. It therefore avoids the common visual overestimation of severity that leads to unnecessary bypass surgery or angiogram catheter procedures. The basis for these three applications has been proven in high quality scientific journals including Circulation, the Journal of the American College of Cardiology, the Journal of Nuclear Medicine and the Journal of Nuclear Cardiology.

This integrated clinical software bundle is an essential part of Positron's product solutions that further differentiates Positron from larger PET manufactures through its superior integrated cardiac PET products in the growing cardiac PET market.

In conjunction with Positron's software R&D efforts, the Company also announces the release of Positron version A3.7 software. The software release incorporates the LGA/HA algorithms, a cardiac normal database and enhancements for quantification, usability and predictability that are specific and unique to Positron PET software. Griff Miller, EVP of Software and IT of Positron stated, "The release of A3.7 is the culmination of more than a decade of data and up-to-date development based on the demands of the PET imaging industry and feedback from our customers and Positron's application specialists."

Joseph Oliverio, President of Positron stated, "The addition of these software systems signifies a critical piece to our further development of state of the art technology and the execution of our business plan. Our comprehensive integrated hardware-software package for total cardiac solutions are ideal for hospitals wanting to differentiate their diagnostic and therapeutic services from competing traditional heart surgery centers. With this software we can bridge the prior critical deficiencies with our integrated quantification of coronary anatomy by CTA, myocardial perfusion and heart function by PET imaging. The release of A3.7 and with the enhancements for quantification will allow Positron users to compete for cholesterol lowering drug trails that assess coronary artery disease reversal thanks to the success Dr. K. Lance Gould has demonstrated using the software as proven in high quality scientific journals."

About Positron:

Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the Weatherhead PET center at the University of Texas Health Science Center in Houston, Texas; The Heart Center of Niagara in Niagara Falls, New York; Beth Israel Medical Center, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta, Georgia; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo, Japan. Additional information may be found at www.positron.com.

Forward Looking Statements

Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or the company's failure to integrate its acquired companies to achieve the synergies and efficiencies described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K.